Priya: Hours after the US midterm results were in, Brussels was already dialing Washington about AI.
Theo: I'm Theo.
Priya: And I'm Priya.
Theo: And this is Money Daily for Monday, November 16th, 2026.
Priya: Today, all our stories are about the same thing: who gets to write the rules for the rest of the world.
Theo: A political shift in the US has the European Union scrambling to set the global standard for artificial intelligence.
Priya: Meanwhile, a major cancer drug invented in China just got a hard 'no' from US regulators.
Theo: And the auditors who somehow missed a multi-billion-dollar corporate collapse are getting a fine that feels more like a slap on the wrist.
Theo: So, let's start with that AI deal. The European Union is making another big push for global rules.
Priya: They see an opening. The FT reports that with President Trump weakened by the midterms, Brussels thinks his 'America First' approach is losing its grip.
Theo: So international deals are back on the table. That's good, right? AI is a global technology; it needs global guardrails.
Priya: Or, the EU is just trying to export its own AI Act and make it the world standard. They call it the 'Brussels Effect.'
Theo: But those rules are focused on risk. High-risk AI, for things like critical infrastructure or hiring, would face strict rules. Low-risk AI, like spam filters, would barely be touched.
Priya: And US tech giants would have to comply to access the massive EU market. That effectively gives Brussels regulatory power over Silicon Valley.
Theo: But isn't that just how standards work? Someone has to set them. We have standards for cars, for food, for toys. Why not for code that can change your life?
Priya: Because it's also about economic advantage. The EU doesn't have a Google or an OpenAI. By writing the rules, they can try to level the playing field for their own companies.
Theo: Okay, so what does this mean for the rest of us?
Priya: It means the AI tools you use could soon have to follow a European playbook. That might make them safer... or it might make them less innovative and more expensive.
Theo: A global standard could also stop a 'Wild West' scenario, where every country has different rules. I'm still calling it a win.
Priya: Next up, we have another regulator saying 'not so fast.' The US Food and Drug Administration has rejected a lung cancer drug that was invented in China.
Theo: Oof. That's a big deal. The drug is ivonescimab, from Summit Therapeutics. It was seen as a huge test case for China's booming biotech sector.
Priya: And the test failed. The FDA said the clinical trial data, which was almost all from China, wasn't good enough. They want a new trial with a diverse, multi-regional population… including Americans.
Theo: That seems… fair? It's the FDA's job to make sure a drug is safe and effective for the people who will actually be taking it in the US.
Priya: It's fair, but it's also a major blow to Beijing's ambition to be a pharma superpower. This sends a message: your domestic data won't cut it in the world's most profitable drug market.
Theo: So wait, is this about science, or is it politics?
Priya: It's always both. The decision raises the bar—and the cost—for Chinese companies. It protects the US market. Some analysts are calling it protectionism in a lab coat.
Theo: But if the science doesn't hold up, what choice do they have? You can't just approve things.
Priya: Tell that to the company. Summit's stock price dropped by a quarter on the news. Billions in market cap just vanished.
Theo: So what's the takeaway here?
Priya: For patients, a potentially promising treatment is now delayed indefinitely. And for everyone, it's a stark reminder of how national interests can slow down global science, keeping new competitors out and drug prices high.
Theo: And finally... speaking of failing to do your job. The auditors for the collapsed finance company Greensill Capital have been fined.
Priya: Oh, this I've got to hear. After a multi-billion dollar disaster that put 50,000 jobs at risk, what's the penalty for 'superficial' auditing?
Theo: The UK's accounting regulator hit the firm, Saffery's, with a fine of... seven hundred thousand pounds.
Priya: Seven. Hundred. Thousand. Pounds. For failing to notice a company vaporizing billions of dollars. That's not a fine. That's a rounding error.
Theo: Well, the regulator said there were 'recurring failures' and a 'lack of professional scepticism'. Apparently Saffery's missed some very obvious red flags in the 2019 books.
Priya: My point exactly! It's a textbook case of terrible auditing, and the penalty is less than what one top executive at these firms makes in a year. It's just the cost of doing business.
Theo: But—
Priya: And! Get this. The FT notes the original fine was supposed to be one million pounds, but Saffery's got a 30% discount for cooperating.
Theo: A discount? For cooperating with the investigation into your own failure? Wow.
Priya: It's a joke. It shows the watchdogs have no teeth. It’s like giving a bank robber a shorter sentence because he told you where he stashed the cash.
Theo: So what's the lesson for the rest of us?
Priya: The lesson is that an 'audited' stamp of approval can be nearly meaningless. You have to be skeptical—even of the people paid to be skeptical for you.
Theo: Alright, let's do a quick recap.
Priya: The EU is making a power play to become the world's AI referee.
Theo: A promising cancer drug developed in China gets blocked from the US market over questions about its data.
Priya: And the auditors who missed the Greensill implosion get a fine that costs less than their Christmas party.
Theo: And before we go, a quick one. Did you know today, November 16th, is National Fast Food Day in the US?
Priya: Let me guess. You're celebrating with a 'globally harmonized' burger and some 'clinically trialed' fries?
Theo: Exactly. Just making sure the menu has been properly audited first.
Priya: That is it for Money Daily. Please don't audit your lunch.
Theo: We'll see you tomorrow. Thanks for listening.
This show is made with AI: the hosts’ voices are synthetic and the scripts are AI-assisted. Every story links to its original source.